TSE:4563Biotechs
AnGes (TSE:4563) Quarterly Loss Persistence Reinforces Bearish Funding Risk Narratives
AnGes (TSE:4563) has wrapped up FY 2025 with Q4 revenue of ¥228 million and a basic EPS loss of ¥1.12, alongside a net income loss of ¥435 million. Over the past few quarters, revenue has moved from ¥169 million in Q1 2025 to ¥245 million in Q2, ¥232 million in Q3 and now ¥228 million in Q4. Basic EPS losses over that stretch have ranged between ¥1.12 and ¥7.91. With trailing twelve month net income at a loss of ¥5.1 billion and EPS at a loss of ¥14.44, the latest numbers keep the focus...